📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
UFLEX Commissions 39,600 MTA Recycling Unit for PET Bottles and Mixed Plastics in Noida
UFLEX Limited has successfully commissioned its new recycling facility in Noida as of April 30, 2026. The unit is designed to process PET bottles and mixed plastics with a significant capacity of 39,600 MTA. This project, initially announced in February 2025, strengthens the company's commitment to the circular economy and sustainable packaging. The commissioning marks a key milestone in the company's operational expansion and ESG initiatives.
Key Highlights
Successfully commissioned the recycling unit in Noida on April 30, 2026
Total processing capacity of the new unit stands at 39,600 MTA
Facility is equipped to handle both PET bottles and mixed plastic waste
Project completion follows the initial announcement made on February 14, 2025
💼 Action for Investors
Investors should view this as a positive development that enhances UFLEX's ESG profile and operational capacity. Monitor the impact of this facility on the company's green product portfolio and overall margins in the coming quarters.
Loading analysis...
UFLEX Targets 24 Billion Aseptic Pack Capacity by FY26; Plans Major Global Expansions
UFLEX Limited is aggressively scaling its high-margin aseptic liquid packaging business, aiming to double its capacity to 24 billion packs per year by FY2026. The company is set to commission a new 12 billion pack plant in Egypt and an 80 million capacity WPP bag facility in Mexico during 2026. With a global manufacturing capacity of over 1.35 million MTPA, UFLEX is well-positioned to capitalize on India's packaging market, which is projected to grow at a 10.2% CAGR through 2027. Recent trends show a broad-based decline in raw material costs like PTA and MEG, which may support margin recovery.
Key Highlights
Aiming to reach 24 billion aseptic carton packs per year capacity by FY2026 from the current 12 billion.
Total global manufacturing capacity stands at 1,351,910 MTPA across 17 units and 150+ countries.
Commissioning a 12 billion pack aseptic plant in Egypt and an 80 million WPP bag facility in Mexico in 2026.
Setting up two new recycling plants in Noida for PCR PET and PCR MLP to enhance sustainability profile.
India's packaging market is forecasted to grow from $102 billion in 2023 to $150 billion by 2027.
💼 Action for Investors
Investors should track the timely commissioning of the Egypt and Mexico facilities as they are critical for the next leg of growth. The shift toward high-margin aseptic packaging and recycled plastics (PCR) is a positive strategic move for long-term value creation.
Loading analysis...
UFLEX Q3 FY26: PAT at Rs 361 Mn; Aseptic Packaging Volumes Rise to 1.8 Bn Packs
UFLEX reported Q3 FY26 revenue of Rs 36,329 million, a 3.8% YoY decline due to volume softness and pricing pressure, but achieved a PAT of Rs 361 million, up 34% sequentially. The aseptic packaging business showed steady growth with volumes rising to 1.8 billion packs in Q3, and management has set an ambitious target of 8.5 billion packs for FY27. Management indicated that debt levels have likely peaked as major expansion projects in Egypt, India, and Mexico near completion. Normalized EBITDA margins improved to 12.1%, a 200 bps expansion quarter-on-quarter, driven by operational discipline.
Key Highlights
Q3 FY26 PAT stood at Rs 361 million with an EPS of Rs 5.01 per share.
Normalized EBITDA grew 12.8% sequentially to Rs 4,395 million with margins at 12.1%.
Aseptic liquid packaging volumes grew 4.4% in 9M FY26 to 5.9 billion packs.
Three major projects in Egypt, India, and Mexico are nearing the commissioning stage.
Management expects aseptic packaging sales to reach 8.5 billion packs in the next fiscal year.
💼 Action for Investors
Investors should focus on the commissioning of the Egypt and Mexico projects as key drivers for EBITDA growth and debt reduction. The recovery in film pricing and growth in the high-margin aseptic segment provide a constructive outlook for the stock.
Loading analysis...
UFLEX to Acquire 28% Stake in Ampin C&I Power for Rs 6.67 Cr for Captive Hybrid Power
UFLEX Limited has entered into a Power Purchase Agreement and Share Subscription Agreement to acquire a 28% equity stake in Ampin C&I Power Twenty-Seven Private Limited. The investment, totaling Rs 6.67 crore, is aimed at sourcing hybrid (Solar + Wind) power on a long-term basis. This move follows the captive power plant policy, which requires users to hold at least a 26% stake in the generating entity. The target company is a newly incorporated entity focused on renewable energy generation in India.
Key Highlights
Acquisition of 28% equity stake involving 66,66,000 shares at Rs 10 each.
Total cash consideration for the investment is Rs 6.67 crore.
Investment facilitates long-term access to hybrid (Solar and Wind) power for captive use.
Target entity is a newly incorporated company (July 2025) with zero current turnover.
Transaction is expected to be completed within 7 business days.
💼 Action for Investors
This is a strategic move to lower long-term energy costs and improve ESG ratings. Investors should view this as a positive step toward operational efficiency and sustainability.
Loading analysis...
UFLEX Targets 24 Billion Aseptic Pack Capacity by FY26 Amid Global Expansion
UFLEX Limited is aggressively scaling its operations with a total global capacity of 1,351,910 MTPA across 17 manufacturing units. The company is on track to reach a nameplate capacity of 24 billion aseptic liquid packs per year by FY2026, supported by a new 12 billion pack plant in Egypt. Additional 2026 projects include an 80 million capacity WPP bag facility in Mexico and new recycling plants in Noida. The company aims to capitalize on India's projected 10.2% packaging market CAGR and a resilient 7.4% GDP growth forecast for FY26.
Key Highlights
Total global manufacturing capacity reaches 1,351,910 MTPA across films, resins, and chemicals.
Aseptic liquid packaging capacity set to double to 24 billion packs per year by FY2026.
Planned commissioning of a 12 billion packs/annum aseptic plant in Egypt and 80 million WPP bag facility in Mexico in 2026.
Upcoming 54,000 MTPA BOPP line expansion in Dharwad, India, to strengthen domestic presence.
Focus on sustainability with new PCR PET and PCR MLP recycling plants being established in Noida.
💼 Action for Investors
Investors should focus on the timely execution of the Egypt and Mexico expansions as these high-margin segments are critical for valuation re-rating. Monitor the recovery in BOPET film pricing which has shown recent quarter-on-quarter improvement.
Loading analysis...
UFLEX Q3 FY26: Normalized EBITDA Rises 12.8% QoQ to Rs 4,395 Mn Despite Revenue Dip
UFLEX reported a mixed performance for Q3 FY26, with revenue declining 3.8% YoY to Rs 36,329 million due to lower packaging film volumes and realization pressures. However, normalized EBITDA showed a sequential recovery, growing 12.8% QoQ to Rs 4,395 million with margins expanding by 200 bps to 12.1%. The company is heavily investing in growth, with major capex projects in Egypt, Mexico, and India totaling over Rs 4,342 million in Q3 alone. While domestic and US markets faced headwinds from inventory destocking and soft demand, management expects a recovery in Q4 FY26 driven by easing imports and improved utilization.
Key Highlights
Q3 FY26 Revenue stood at Rs 36,329 Mn, down 3.8% YoY and 5.9% QoQ.
Normalized EBITDA reached Rs 4,395 Mn, up 12.8% QoQ but down 16.1% YoY.
Sales volume for Q3 FY26 was 151,245 MT, reflecting a 3.7% YoY decline.
Incurred Rs 4,342 Mn capex in Q3 for global projects including Egypt Aseptic and Mexico WPP plants.
Net debt remains substantial at Rs 81,810 Mn as of December 31, 2025.
💼 Action for Investors
Investors should closely monitor the timely commissioning of the Egypt Aseptic and Mexico WPP facilities in FY26, which are critical for future volume growth. While sequential margin improvement is positive, the high debt levels and global demand volatility warrant a cautious approach.
Loading analysis...
UFlex Q3 FY26: Normalized EBITDA Grows 12.8% QoQ to Rs 4,395 Mn; PAT at Rs 486 Mn
UFlex reported a resilient Q3 FY26 with consolidated revenue of Rs 36,329 million, down 3.8% YoY but showing sequential margin improvement. Normalized EBITDA grew 12.8% QoQ to Rs 4,395 million, with margins expanding 200 bps to 12.1% despite global trade uncertainties and import-led price pressures. For the nine-month period (9M FY26), the company returned to profitability with a PAT of Rs 1,211 million compared to a loss of Rs 262 million in the previous year. Management remains constructive on the outlook, supported by upcoming capacity expansions in Egypt and Mexico.
Key Highlights
Normalized EBITDA increased 12.8% QoQ to Rs 4,395 million, with margins improving to 12.1%.
9M FY26 PAT stood at Rs 1,211 million, a significant turnaround from a net loss of Rs 262 million in 9M FY25.
Packaging segment sales volume grew 7.6% YoY to 36,280 MT, while Packaging Films volume declined 6.8% YoY.
Consolidated sales volume for Q3 FY26 was 151,245 MT, down 3.7% YoY and 6.2% QoQ.
India remains the largest revenue contributor at 46.1%, followed by the Americas at 18.9% and Europe at 17.4%.
💼 Action for Investors
Investors should focus on the sequential recovery in margins and the commissioning of new capacities in Egypt and Mexico as potential growth catalysts. However, caution is advised regarding global trade barriers and domestic import pressures that continue to impact the packaging films segment.
Loading analysis...
UFLEX Q3 FY26 Consolidated Net Profit Drops 73.6% YoY to ₹36.15 Crore
UFLEX reported a consolidated revenue of ₹3,612 crore for Q3 FY26, a decline of 3.3% compared to ₹3,734.7 crore in the same quarter last year. Net profit after minority interest fell sharply by 73.6% YoY to ₹36.15 crore, though it showed a sequential recovery from ₹26.9 crore in Q2 FY26. Profitability was impacted by rising finance costs, which reached ₹192.9 crore, and a one-time exceptional charge of ₹12.45 crore related to New Labour Code provisions. Additionally, the company is currently contesting a significant Income Tax demand of ₹412.81 crore.
Key Highlights
Consolidated Revenue from operations stood at ₹3,612 crore, down 3.3% YoY from ₹3,734.7 crore.
Net Profit after tax (attributable to owners) plummeted to ₹36.15 crore from ₹136.8 crore in Q3 FY25.
Finance costs rose to ₹192.9 crore in Q3 FY26, up from ₹174.3 crore in the year-ago period.
Recognized an exceptional expense of ₹1,245 lacs (₹12.45 crore) due to legislative amendments in Labour Codes.
Ongoing legal risk with an Income Tax demand of ₹41,280.99 lacs (₹412.81 crore) currently under appeal.
💼 Action for Investors
Investors should exercise caution given the significant year-on-year contraction in margins and the large outstanding tax demand. The stock may remain under pressure until there is clarity on the tax litigation and an improvement in the core flexible packaging segment's profitability.
Loading analysis...
UFLEX CFO Rajesh Bhatia Retires Effective February 4, 2026
UFLEX Limited has announced the retirement of Mr. Rajesh Bhatia from his position as Group President (F&A) and Chief Financial Officer. The cessation of his role as a Key Managerial Personnel (KMP) is effective from the close of business hours on February 4, 2026. This change is attributed to superannuation, representing a planned leadership transition within the company's finance department. Investors should note that a successor has not yet been named in this specific regulatory filing.
Key Highlights
Mr. Rajesh Bhatia ceased to be the CFO and KMP effective February 4, 2026
The departure is due to superannuation (retirement) from his role as Group President (F&A)
He also ceases to be the authorized person for determining materiality under SEBI Regulation 30(5)
The disclosure was made in compliance with SEBI Listing Regulations, 2015
💼 Action for Investors
Investors should monitor future filings for the appointment of a new CFO to ensure continuity in financial management. As this is a planned retirement, it is unlikely to impact short-term stock performance.